Q-omics provides the consensus-scored NUDT21 profile across patient tissues and cancer cell-line models. NUDT21 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NUDT21 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, NUDT21 protein abundance shows 26,829 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where NUDT21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUDT21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUDT21 survival associations across molecular data types. NUDT21 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUDT21 RNA expression–survival associations across cancer types. High NUDT21 expression shows unfavorable associations in ACC, PAAD, MESO and LIHC, but favorable associations in KIRC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NUDT21 RNA expression.
This table summarizes NUDT21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for NUDT21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUDT21 shows lower tumor expression in KIRC, THCA and KICH and higher tumor expression in HNSC, COAD and BLCA. The HNSC box plot shows higher NUDT21 RNA expression in tumor versus normal tissue (log2 FC = +0.722, t-test p < 0.001).
This table shows molecular features associated with NUDT21 in patient tissues and cancer cell lines. In patient samples, NUDT21 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NUDT21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
